title: Efficacy of Anti-TNF-α Therapy for the Treatment of Non-infectious Uveitis: A Retrospective Study of 21 Patients.
abstract: OBJECTIVE
  To assess the efficacy of anti-TNF alpha (TNF-α) therapy in patients with non-infectious uveitis.
  
  
  METHODS
  This was a monocentric observational study of 21 patients with non-infectious uveitis treated with anti-TNF-alpha. The primary endpoint was the control of ocular inflammation. The secondary endpoints included the study of macular thickness and visual acuity, changes in other treatments, and adverse effects.
  
  
  RESULTS
  The etiologies of uveitis were Behçet disease (33.3%), birdshot (14.3%), sarcoidosis (9.5%), and idiopathic uveitis (42.9%). Ocular inflammation was controlled at 3 months for 80.9% of patients, at 6 months for 94.7%, at 12 months for 83.3%, and at >12 months for 86.7%. Central macular thickness improved from 452 µm at baseline to 307.5 µm at 12 months (p = 0.002). Visual acuity also improved from 0.51(logMAR) before treatment to 0.24 at 12 months. The mean daily dose of prednisone decreased from 19.7 mg before treatment to 5.2 mg at 12 months (p < 0.001). A total of 9.5% of patients experienced serious side-effects.
  
  
  CONCLUSIONS
  Our study confirms the efficacy of anti-TNF for the control of short-term and long-term ocular inflammation, with high rates of complete clinical remission.
authors: a Department of Ophthalmology , University Hospital, Place Amélie Raba Léon , Bordeaux , France.
authors: Audrey-Elodie
authors: AE
authors: Mercier
authors: b Internal Medicine , University Hospital , Bordeaux , France.
authors: Emmanuel
authors: E
authors: Ribeiro
authors: a Department of Ophthalmology , University Hospital, Place Amélie Raba Léon , Bordeaux , France.|c INSERM Unit 897 - Epidemiology and Biostatistics, INSERM, ISPED , Bordeaux , France.|d University of Bordeaux , Bordeaux , France.
authors: Jean-François
authors: JF
authors: Korobelnik
authors: a Department of Ophthalmology , University Hospital, Place Amélie Raba Léon , Bordeaux , France.|c INSERM Unit 897 - Epidemiology and Biostatistics, INSERM, ISPED , Bordeaux , France.|d University of Bordeaux , Bordeaux , France.
authors: Marie-Noëlle
authors: MN
authors: Delyfer
authors: a Department of Ophthalmology , University Hospital, Place Amélie Raba Léon , Bordeaux , France.
authors: Marie-Bénédicte
authors: MB
authors: Rougier
mesh_terms: D000068879:Adalimumab / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D000069285:Infliximab / Q000627:therapeutic use*; D008266:Macula Lutea / Q000000981:diagnostic imaging; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014605:Uveitis / Q000188:drug therapy* / Q000503:physiopathology; D014792:Visual Acuity / Q000502:physiology; D055815:Young Adult
chemical_list: D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab
keywords: Adalimumab; anti-TNF-α; infliximab; non-infectious uveitis; refractory uveitis